Valproic acid modulates radiation-enhanced matrix metalloproteinase activity and invasion of breast cancer cells

References

• Artacho-Cordón A, Artacho-Cordón F, Ríos-Arrabal S, Calvente I, Núñez MI. 2012a. Tumor microenvironment and breast cancer progression: a complex scenario. Cancer Biol Ther 13:14–24.
   PubMed Web of Science ®Google Scholar
• Artacho-Cordón F, Ríos-Arrabal S, Lara P, Artacho-Cordón A, Calvente I, Núñez MI. 2012b. Matrix metalloproteinases: potential therapy to prevent the development of second malignancies after breast radiotherapy. Surgical Oncol 21:e143–151.
   PubMed Web of Science ®Google Scholar
• Barcellos-Hoff MH, Park C, Wright EG. 2005. Radiation and the microenvironment – tumorigenesis and therapy. Nature Rev Cancer 5:867–875.
   PubMed Web of Science ®Google Scholar
• Barcellos-Hoff MH, Ravani SA. 2000. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res 60:1254–1260.
   PubMed Web of Science ®Google Scholar
• Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. 2005. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120:303–313.
   PubMed Web of Science ®Google Scholar
• Bouchard G, Bouvette G, Therriault H, Bujold R, Saucier C, Paquette B. 2013. Pre-irradiation of mouse mammary gland stimulates cancer cell migration and development of lung metastases. Br J Cancer 109:1829–1838.
   PubMed Web of Science ®Google Scholar
• Cordes N, Hansmeier B, Beinke C, Meineke V, Van Beuningen D. 2003. Irradiation differentially affects substratum-dependent survival, adhesion, and invasion of glioblastoma cell lines. Br J Cancer 89:2122–2132.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Fingleton B, Matrisian LM. 2002. Matrix metalloproteinase inhibitors and cancer – trials and tribulations. Science 295:2387–2392.
   PubMed Web of Science ®Google Scholar
• De Schutter H, Nuyts S. 2009. Radiosensitizing potential of epigenetic anticancer drugs. Anti-Cancer Agents Medicinal Chem 9: 99–108.
   PubMed Web of Science ®Google Scholar
• Debeb BG, Xu W, Mok H, Li L, Robertson F, Ueno NT, Reuben J, Lucci A, Cristofanilli M, Woodward WA. 2010. Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. Int J Radiat Oncol Biol Phys 76:889–895.
   PubMed Web of Science ®Google Scholar
• Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. 2008. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34:206–222.
   PubMed Web of Science ®Google Scholar
• Eck SM, Blackburn JS, Schmucker AC, Burrage PS, Brinckerhoff CE. 2009. Matrix metalloproteinase and G protein coupled receptors: co-conspirators in the pathogenesis of autoimmune disease and cancer. J Autoimmunity 33:214–221.
   PubMed Web of Science ®Google Scholar
• Eke I, Cordes N. 2011. Radiobiology goes 3D: how ECM and cell morphology impact on cell survival after irradiation. Radiother Oncol 99:271–278.
   PubMed Web of Science ®Google Scholar
• Fujita M, Otsuka Y, Yamada S, Iwakawa M, Imai T. 2011. X‐ray irradiation and Rho‐kinase inhibitor additively induce invasiveness of the cells of the pancreatic cancer line, MIAPaCa‐2, which exhibits mesenchymal and amoeboid motility. Cancer Sci 102:792–798.
   PubMed Web of Science ®Google Scholar
• Furmanova-Hollenstein P, Broggini-Tenzer A, Eggel M, Millard A-L, Pruschy M. 2013. The microtubule stabilizer patupilone counteracts ionizing radiation-induced matrix metalloproteinase activity and tumor cell invasion. Radiat Oncol 8:105.
   PubMed Web of Science ®Google Scholar
• Groselj B, Sharma N, Hamdy F, Kerr M, Kiltie A. 2013. Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br J Cancer 108:748–754.
   PubMed Web of Science ®Google Scholar
• Hehlgans S, Storch K, Lange I, Cordes N. 2013. The novel HDAC inhibitor NDACI054 sensitizes human cancer cells to radiotherapy. Radiother Oncol 109:126–132.
   PubMed Web of Science ®Google Scholar
• Kawano T, Akiyama M, Agawa-Ohta M, Mikami-Terao Y, Iwase S, Yanagisawa T, Ida H, Agata N, Yamada H. 2010. Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation. Int J Oncol 37:787–795.
   PubMed Web of Science ®Google Scholar
• Köhrmann A, Kammerer U, Kapp M, Dietl J, Anacker J. 2009. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature. BMC Cancer 9:188.
   PubMed Web of Science ®Google Scholar
• Lemay R, Archambault M, Tremblay L, Bujold R, Lepage M, Paquette B. 2011. Irradiation of normal mouse tissue increases the invasiveness of mammary cancer cells. Int J Radiat Biol 87:472–482.
   PubMed Web of Science ®Google Scholar
• Li T, Zeng Z, Wang L, Qiu S, Zhou J, Zhi X, Yu H, Tang Z. 2011. Radiation enhances long-term metastasis potential of residual hepatocellular carcinoma in nude mice through TMPRSS4-induced epithelial-mesenchymal transition. Cancer Gene Ther 18:617–626.
   PubMed Web of Science ®Google Scholar
• Lin HY, Chen CS, Lin SP, Weng JR, Chen CS. 2006. Targeting histone deacetylase in cancer therapy. Medicinal Res Rev 26:397–413.
   PubMed Web of Science ®Google Scholar
• Mitmaker EJ, Griff NJ, Grogan RH, Sarkar R, Kebebew E, Duh QY, Clark OH, Shen WT. 2011. Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors. Surgery 149:504–511.
   PubMed Web of Science ®Google Scholar
• Moncharmont C, Levy A, Guy J-B, Falk AT, Guilbert M, Trone J-C, Alphonse G, Gilormini M, Ardail D, Toillon R-A. 2014. Radiation-enhanced cell migration/invasion process: a review. Crit Rev Oncol/Hematol 92:133–142.
   PubMed Web of Science ®Google Scholar
• Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, Tucker SL, Ismail S, Stevens C, Meyn RE. 2005. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 11:4912–4922.
   PubMed Web of Science ®Google Scholar
• Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE. 2006. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of γ-H2AX foci. Molec Cancer Therapeut 5:1967–1974.
   PubMed Web of Science ®Google Scholar
• Nakopoulou L, Tsirmpa I, Alexandrou P, Louvrou A, Ampela C, Markaki S, Davaris PS. 2003. MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival. Breast Cancer Res Treat 77:145–155.
   PubMed Web of Science ®Google Scholar
• Nambiar DK, Rajamani P, Singh RP. 2015. Silibinin attenuates ionizing radiation-induced pro-angiogenic response and EMT in prostate cancer cells. Biochem Biophys Res Communic 456:262–268.
   PubMed Web of Science ®Google Scholar
• Neri A, Megha T, Bettarini F, Tacchini D, Mastrogiulio MG, Marrelli D, Pinto E, Tosi P. 2012. Is tissue inhibitor of metalloproteinase-1 a new prognosticator for breast cancer? An analysis of 266 cases. Human Pathol 43:1184–1191.
   PubMed Web of Science ®Google Scholar
• Nguyen DH, Oketch-Rabah HA, Illa-Bochaca I, Geyer FC, Reis-Filho JS, Mao JH, Ravani SA, Zavadil J, Borowsky AD, Jerry DJ. 2011. Radiation acts on the microenvironment to affect breast carcinogenesis by distinct mechanisms that decrease cancer latency and affect tumor type. Cancer Cell 19:640–651.
   PubMed Web of Science ®Google Scholar
• Noë V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel M. 2001. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114:111–118.
   PubMed Web of Science ®Google Scholar
• Overall CM, López-Otín C. 2002. Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nature Rev Cancer 2:657–672.
   PubMed Web of Science ®Google Scholar
• Palmieri D, Lockman PR, Thomas FC, Hua E, Herring J, Hargrave E, Johnson M, Flores N, Qian Y, Vega-Valle E. 2009. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res 15:6148–6157.
   PubMed Web of Science ®Google Scholar
• Paquette B, Therriault H, Desmarais G, Wagner R, Royer R, Bujold R. 2011. Radiation-enhancement of MDA-MB-231 breast cancer cell invasion prevented by a cyclooxygenase-2 inhibitor. Br J Cancer 105:534–541.
   PubMed Web of Science ®Google Scholar
• Park SY, Jun J, Jeong KJ, Heo HJ, Sohn JS, Lee HY, Park CG, Kang J. 2011. Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncol Rep 25:1677–1681.
   PubMed Web of Science ®Google Scholar
• Ríos-Arrabal S, Artacho-Cordón F, León J, Román-Marinetto E, del Mar Salinas-Asensio M, Calvente I, Núñez MI. 2013. Involvement of free radicals in breast cancer. SpringerPlus 2:404.
   PubMed Web of Science ®Google Scholar
• Schneider U. 2011. Modeling the risk of secondary malignancies after radiotherapy. Genes 2:1033–1049.
   PubMed Web of Science ®Google Scholar
• Schrohl A-S, Christensen IJ, Pedersen AN, Jensen V, Mouridsen H, Murphy G, Foekens JA, Brünner N, Holten-Andersen MN. 2003. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Molec Cellul Proteom 2:164–172.
   PubMed Web of Science ®Google Scholar
• Sendon-Lago J, Seoane S, Eiro N, Bermudez MA, Macia M, Garcia-Caballero T, Vizoso FJ, Perez-Fernandez R. 2014. Cancer progression by breast tumors with Pit-1-overexpression is blocked by inhibition of Metalloproteinase (MMP)-13. Breast Cancer Res 16:505.
   PubMed Web of Science ®Google Scholar
• Shabason JE, Tofilon PJ, Camphausen K. 2011. Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J Cellul Molec Med 15:2735–2744.
   PubMed Web of Science ®Google Scholar
• Shiao SL, Coussens LM. 2010. The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia 15:411–421.
   PubMed Web of Science ®Google Scholar
• Shoji M, Ninomiya I, Makino I, Kinoshita J, Nakamura K, Oyama K, Nakagawara H, Fujita H. Tajima H, Takamura H. 2012. Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma. Int J Oncol 40:2140–2146.
   PubMed Web of Science ®Google Scholar
• Vigushin DM, Coombes RC. 2002. Histone deacetylase inhibitors in cancer treatment. Anti-Cancer Drugs 13:1–13.
   PubMed Web of Science ®Google Scholar
• Visse R, Nagase H. 2003. Matrix metalloproteinases and tissue inhibitors of metalloproteinases structure, function, and biochemistry. Circulat Res 92:827–839.
   PubMed Web of Science ®Google Scholar
• Wang F, Qi Y, Li X, He W, Fan QX, Zong H. 2013. HDAC inhibitor trichostatin A suppresses esophageal squamous cell carcinoma metastasis through HADC2 reduced MMP-2/9. Clin Investigat Med 36:E87–94.
   PubMed Web of Science ®Google Scholar
• Yu J, Mi J, Wang Y, Wang A, Tian X. 2011. Regulation of radiosensitivity by HDAC inhibitor trichostatin A in the human cervical carcinoma cell line Hela. Eur J Gynaecolog Oncol 33:285–290.
   Web of Science ®Google Scholar
• Zhang HJ, Zhao W, Venkataraman S, Robbins ME, Buettner GR, Kregel KC, Oberley LW. 2002. Activation of matrix metalloproteinase-2 by overexpression of manganese superoxide dismutase in human breast cancer MCF-7 cells involves reactive oxygen species. J Biolog Chem 277:20919–20926.
   PubMed Web of Science ®Google Scholar
• Zhong HM, Ding QH, Chen WP, Luo RB. 2013. Vorinostat, a HDAC inhibitor, showed anti-osteoarthritic activities through inhibition of iNOS and MMP expression, p38 and ERK phosphorylation and blocking NF-κB nuclear translocation. Int Immunopharmacol 17:329–335.
   PubMed Web of Science ®Google Scholar
• Zucker S, Cao J, Chen WT. 2000. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19:6642–6650.
   PubMed Web of Science ®Google Scholar